Tag Archives: GlaxoSmithKline

Pharma Celebrates its Own

By Andrew Sheivachman | Published: October 7, 2009

At the gala ceremony for the 2009 Prix Galien USA award on October 1, a paradigm shift in drug development took center stage. “The most successful new [cancer] therapies will be based on a precise molecular understanding of disease basis—that’s exactly what we did with Gleevec,” said keynote speaker Brian Druker, director of the Oregon Health [...]

Posted in Events | Also tagged American Museum of Natural History, business, Clinical trial, Columbia University, Elie Wiesel, Harvard School of Public Health, Health, Health care, Jeffrey Sachs, Pharmaceutical drug, Prix Galien, Public health, United States | Leave a comment

Prix Galien Push for Private/Public Collaboration

By Andrew Sheivachman | Published: October 6, 2009

Preceding the presentation of the 2009 Prix Galien USA prizes, last Tuesday, a round table discussion was conducted at the American Museum of Natural History on the subject of how public and private collaboration can increase innovation and contribute to saving lives around the world. The talk included Leonard Bell of Alexion Pharmaceuticals, Barry Bloom [...]

Posted in Events | Also tagged Africa, American Museum of Natural History, Harvard School of Public Health, Jeffrey Sachs, Novartis, Prix Galien, Public health, United States | Leave a comment

H1N1 Vaccine Quantities to Fall Short of Predictions

By George Koroneos | Published: August 19, 2009

Image by â– Guerry via Flickr The US may not have as many H1N1 flu vaccines available from the get-go as originally anticipated, CBS News reported on Tuesday. According to the report, approximately 45 million doses will be available in mid-October—that’s down from the original plan of 120 million doses. The new plan calls for [...]

Posted in Manufacturing | Also tagged Canada, Health, Influenza, Influenza A virus subtype H1N1, Influenza pandemic, Influenza vaccine | 2 Comments

GSK Signs $120M Deal to Market DMab Overseas

By George Koroneos | Published: July 29, 2009

Image via Wikipedia In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis treatment denosumab—currently pending FDA approval. GSK will paying $120 million up front (along with royalties) to mutually market denosumab, or DMab, in regions where Amgen [...]

Posted in Deals, News, Technology | Also tagged Amgen, Australia, Canada, denosumab, Dmab, Market, Mexico, New Zealand, sales force, U.S. Food and Drug Administration, United States | 1 Comment

Chantix and Zyban Get Boxed Warnings

By George Koroneos | Published: July 1, 2009

Image via Wikipedia FDA announced yesterday afternoon that the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion) must bear black box warnings for serious mental health symptoms, including changes in behavior, hostility, depression, and attempted suicide. In addition to being used in smoking cessation, buproprion is also marketed as an atypical antidepressant under the brand name Wellbutrin, [...]

Posted in Strategy | Also tagged Clinical trial, Health, Pfizer, Smoking cessation, Tobacco, U.S. Food and Drug Administration, Varenicline | 6 Comments